Tekla Life Sciences Investors Fund (HQL) is closed-end fund invests in a number of publicly traded a...
Activists Eyes Bristol-Myers
04/20/2017 2:50 am EST
The news that activist investor Carl Icahn has taken a position in Bristol-Myers Squibb (BMY) is fueling takeover speculation.
And he's not alone. Jana Partners LLC took a stake in the company last year after Bristol-Myer's lung cancer treatment, Opdivo, fared poorly in a late-stage study.
In a deal with Jana, the company agreed to add three directors to its board and to launch a $2 billion accelerated share repurchase program.
But perhaps the best reason is that the company might be a bargain. While the shares rose around 15 percent in February on acquisition rumors, more meaningful is that the company has several promising studies in the works testing Opdivo as a treatment for other cancers.
Plus the company has a robust pipeline of other drugs at various phases of testing. Several of its existing drugs are posting double-digit sales increases.
The company has a hefty cache of about $8.6 billion in cash or cash equivalents, which it could use for more product development or a strategic acquisition. And we like the reliable 2.7 percent dividend.
Related Articles on HEALTHCARE
Minnesota-based UnitedHealth Group (UNH) is the world’s largest health care company and a top ...
Cardinal Health (CAH) is one of the “big three” wholesale drug distributors in the Unite...
As the world faces an increasing onslaught of new threats from biological and chemical weapons, viru...